E3810 + E3810 + Teprenone
Phase 2/3Completed 0 watching 0 views this week📈 Rising
65
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Conditions
Gastric or Duodenal Ulcers Caused by Low-dose Aspirin
Trial Timeline
Jul 1, 2011 → Jun 1, 2013
NCT ID
NCT01397448About E3810 + E3810 + Teprenone
E3810 + E3810 + Teprenone is a phase 2/3 stage product being developed by Eisai for Gastric or Duodenal Ulcers Caused by Low-dose Aspirin. The current trial status is completed. This product is registered under clinical trial identifier NCT01397448. Target conditions include Gastric or Duodenal Ulcers Caused by Low-dose Aspirin.
Hype Score Breakdown
Clinical
22
Activity
15
Company
10
Novelty
7
Community
8
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01397448 | Phase 2/3 | Completed |
Competing Products
20 competing products in Gastric or Duodenal Ulcers Caused by Low-dose Aspirin